SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune announced alignment with the FDA on a path forward for…

Replimune, Inc. · PRESS-RELEASE filed May 29, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 29, 2026 at 08:00 ET

Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with the FDA committing to prioritize review. This is a significant regulatory de-risking event for a clinical-stage biotech with no approved products, transforming the company's outlook.

  • Replimune and FDA aligned on path forward for RP1 BLA resubmission for advanced melanoma
  • BLA resubmission expected in coming days; FDA will treat as urgent matter and prioritize review
  • RP1 is Replimune's lead product candidate; company has no approved products
  • Approximately 8,500 advanced melanoma deaths annually; ~50% of patients fail checkpoint inhibitor therapy

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access